<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03600831</url>
  </required_header>
  <id_info>
    <org_study_id>huaianzhuweiguo</org_study_id>
    <nct_id>NCT03600831</nct_id>
  </id_info>
  <brief_title>Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma</brief_title>
  <official_title>A Randomized Phase Ⅱ/Ⅲ Trial of Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huai'an First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Huai'an Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>lian shui county People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>xuyi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese People's Liberation Army No. 82 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Huai'an First People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effect of postoperative concurrent
      chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal
      squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>From date of randomization to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>From the date of randomization to the date of first observation of disease progression, or relapse, or death due to any cause。</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization to death from any cause, assessed up to 3 years</time_frame>
    <description>From the date of randomization until the date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related toxicities</measure>
    <time_frame>From the date of randomization until six months after treatment completion</time_frame>
    <description>Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCICTC), version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life(QOL)</measure>
    <time_frame>1 year</time_frame>
    <description>Quality of life of patient will be evaluated using EORTC QLQ-C30. Evaluation of quality of life will be performed every 3 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">434</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>concurrent chemoradiotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>radiotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients in this group will receive radiotherapy alone 50Gy (2.0 Gy/fraction, 5 days a week).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel plus cisplatin</intervention_name>
    <description>cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks</description>
    <arm_group_label>concurrent chemoradiotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)</description>
    <arm_group_label>concurrent chemoradiotherapy group</arm_group_label>
    <arm_group_label>radiotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. biopsy-confirmed esophageal squamous cell carcinoma

          2. age ≤ 70 years old,

          3. Karnofsky performance status ≥ 70,

          4. R0 esophagectomy according to the pathological examination of the resected specimens,

          5. postoperative stage Ⅱ-Ⅳa according to the AJCC 7th edition of tumor-node-metastasis
             (TNM) classification for esophageal carcinoma

          6. Adequate organ functions (1).white blood cell (WBC) ≥3×109⁄L; (2).Absolute neutrophil
             counts (ANC) ≥1.5×109⁄L; (3).Hemoglobin (Hb) ≥10g⁄dl; (4).Platelet (Plt) ≥100×109⁄L;
             (5).Total bilirubin &lt;1.5 upper limit of normal (ULN); (6).Aspartate transaminase (AST)
             ≤2.5 ULN; (7).Alanine aminotransferase (ALT) ≤2.5 ULN; (8).Creatinine ≤1.5 ULN;
             (9).adequate pulmonary function (FEV1&gt;0.8 L;.

          7. no previous treatment or severe complications

          8. Written informed consent

        Exclusion Criteria:

          1. previous treatment with chemotherapy or radiotherapy

          2. greater than 3 months after surgery

          3. complete esophageal obstruction after surgery, esophageal perforation;

          4. other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in
             situ, who survived with no evidence disease for over 3 years;

          5. pregnant or breast-feeding women；

          6. patients with any serious concurrent disease, such as severe diabetes, uncontrolled
             hypertension, serious chronic obstructive pulmonary disease；

          7. drug addiction, Alcoholism or AIDS;

          8. uncontrolled seizures or psychiatric diseases, loss of control over their own
             behavior;

          9. with clear chemotherapy drug allergy

         10. participation in other interventional clinical trials within 30 days;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wei-guo zhu, MD</last_name>
    <phone>+8613511555000</phone>
    <email>jshazwg@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese Peiple's Liberation Army No.82 Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qian-wen Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huai'an second peiple's Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li-qing Zhou, Phd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lianshui County Peoples Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>juan pu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>xuyi peiple's Hospital</name>
      <address>
        <city>Xu Yi</city>
        <state>Jiangsu</state>
        <zip>211700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lian Wang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal neoplasma</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

